The hopeful vaccine news keeps coming: Johnson & Johnson’s single-dose COVID-19 vaccine effective and safe, per FDA analysis

Johnson & Johnson’s single-dose coronavirus vaccine is effective at preventing moderate and severe cases of COVID-19, according to an analysis of the trial data published by the Food and Drug Administration on Wednesday.

The company’s single dose vaccine is 66 percent effective, well within the agency’s standards. The vaccine is also safe to use, according to the analysis.

What might be even more important: The vaccine is more than 85 percent effective at preventing severe cases of COVID-19 and completely prevents hospitalizations and deaths.

Looking ahead, the US could have a third vaccine by this weekend: The information was published ahead of an FDA advisory committee meeting Friday, which will debate whether to grant the vaccine emergency authorization. The promising data gives hope that a third coronavirus vaccine could be authorized as soon as this weekend.